ChemicalBook > CAS DataBase List > Narnatumab
Narnatumab
- Product Name
- Narnatumab
- CAS No.
- 1188275-92-4
- Chemical Name
- Narnatumab
- Synonyms
- Narnatumab;Narnatumab (anti-RON);Research Grade Narnatumab;Research Grade Narnatumab(DHG03401)
- CBNumber
- CB48080840
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Narnatumab Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Narnatumab Chemical Properties,Usage,Production
Uses
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer[1].
in vivo
Narnatumab (2-60 mg/kg; i.p. every 3 days) shows antitumor activity in non-small cell lung cancer (NSCLC) and bladder cancer models in athymic mice[1].
Narnatumab exhibits terminal half-life (t1/2=5.2 d) and achieves antitumor effects at a steady-state plasma trough level of approximately 140 μg/mL in mice[1].
| Animal Model: | Female athymic nu/nu mice (6-8 weeks) were injected NCI-H292 and BFTC-905 cells[1] |
| Dosage: | 2, 20, 60 mg/kg |
| Administration: | I.p. every 3 days for 36 and 18 days |
| Result: | Inhibited tumor growth in a dose-dependent manner. |
References
[1] LoRusso PM, et, al. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2017 Aug;35(4):442-450. DOI:10.1007/s10637-016-0413-0
Narnatumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Narnatumab Suppliers
- Tel
- tp@aladdinsci.com
- Country
- United States
- ProdList
- 57505
- Advantage
- 58
1188275-92-4, NarnatumabRelated Search:
Alacizumab Pegol
Abrilumab
Eldelumab
Tomuzotuximab
Anifrolumab
Erenumab
Teprotumumab
Panitumumab
VeltuzuMab
Rituximab